You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Improved Treatment of Colorectal Cancer with CF10

    SBC: Deep Creek Pharma, LLC            Topic: 102

    PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. CN-105 Improves Functional Outcome After Intracranial Hemorrhage

    SBC: AegisCN LLC            Topic: 106

    Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Programming Metabolically Fit TILs for Immunotherapy

    SBC: LIPO-IMMUNO TECH LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Enhanced MDx: a computational model to optimize pre-analytical pathogen isolation from whole blood

    SBC: Redbud Labs, Inc.            Topic: 400

    ABSTRACTMicroscale simulations have been applied to a number of complex microfluidic systems and biological applications, but existing methods are limited in the scale and scope of problems that are addressable. Thermodynamically constrained averaging theory (TCAT) is an established approach that can be used to formulate customized macroscale models that are consistent with microscale physics and ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. MegaTrans – human transporter machine learning models

    SBC: COLLABORATIONS PHARMACEUTICALS INC            Topic: 400

    Summary Being able to predict interactions with important human transporters would be of value to new drug design to avoid compounds that interact with them and cause undesirable side effects. Conversely, some drug transporters can be used for targeting molecules to specific organs and this may have considerable utility. Understanding the interactions of novel drugs, natural products and environme ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of SP-A Derived Peptidomimetics for the Treatment of Asthma- Phase II

    SBC: RaeSedo, LLC            Topic: NHLBI

    Current treatments for asthma, while reducing exacerbations in a subset of patients by focusing on airway inflammation, do not eliminate them. Asthma exacerbations are a significant cause of morbidity and mortality in asthma as they can lead to airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and lost productivi ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Critical angle reflection imaging for label-free quantification of molecular interactions

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    TITLE: Critical angle reflection imaging (CARi) for label-free quantification of molecular interactions SUMMARYMeasuring molecular interactions of proteins are critical for understanding protein functions and cellular processes, for discovery and validating biomarkers, and for developing and screening drugs. In particular, membrane proteins play key roles in many cellular functions and are the lar ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Affordable sialoglycans and associated reagents for expanded chemoenzymatic production

    SBC: Integrated Micro-Chromatography Systems, Inc.            Topic: 300

    Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of peptide nucleic acid antibiotics

    SBC: NUBAD LLC            Topic: NIAID

    The world is rapidly heading towards a pre-1940’s scenario when it comes to fighting infectious disease. Antimicrobial resistance is a growing problem on a global scale, greatly hampering our abilities to quell worldwide epidemics such as influenza, SARS, COVID-19, tuberculosis and malaria, as well as the simple staphylococcus infection. Unless innovative strategies are developed to produce robu ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low-cost methods to develop aminoglycosides with anti-ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced ot ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government